Small-Cap Stocks Soar as Broader Markets Stagnate

January 8, 2025

DENVER, Colo., Jan 08, 2025 (247marketnews.com) While broader markets remain relatively stagnant, small-cap stocks are defying the trend with significant gains and record-breaking volumes. Investors are buzzing as several small-cap companies hit new highs today, driven by groundbreaking announcements and impressive trading activity.

(NASDAQ:CURR) CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical is leading the charge, skyrocketing over 300% to a high of $7.00 with more than 800,000 trades as of midday. The surge follows this morning’s announcement of a major licensing deal for its innovative oral thin-film drug delivery technology. This technology offers a novel way to deliver medications, positioning the company as a disruptor in the cannabis and nutraceutical industries.

(NASDAQ:VIR) Vir Biotechnology, Inc.
Vir Biotechnology shares are up 67%, trading at $13.40 on the heels of positive Phase 1 clinical trial data. The company revealed promising results for its dual-masked T-cell engagers, VIR-5818 and VIR-5500, targeting HER2-positive solid tumors and metastatic castration-resistant prostate cancer (mCRPC). The trials demonstrate the potential of Vir’s PRO-XTEN™ masking technology to reduce toxicity and improve efficacy, signaling a major advancement in cancer treatment.

(NASDAQ:XHG) Xchange Tec Inc.
Xchange Tec, which recently regained NASDAQ listing compliance, has soared more than 212% today on heavy trading volume exceeding 52 million shares. The surge is fueled by record-breaking quarterly revenue driven by its AI-powered enterprise software solutions. Investors are optimistic about Xchange Tec’s ability to capitalize on growth opportunities in the AI and IoT sectors.

(NASDAQ:SANA) Sana Biotechnology, Inc.
Sana Biotechnology is up 202% on the day, with trading volumes surpassing 98 million shares. The rally follows the company’s announcement of groundbreaking results from a diabetes study, where its gene-editing platform restored insulin production in Type 1 diabetes patients. This breakthrough could redefine diabetes treatment, positioning Sana as a leader in gene-editing technologies.

(NASDAQ:SILO) Silo Pharma, Inc.
Silo Pharma has gained over 100%, trading at $2.29 after securing a patent for its innovative PTSD treatment. The treatment combines psychedelics with advanced delivery systems, addressing critical unmet needs in mental health care. With over 140 million shares traded, Silo Pharma is attracting strong interest as a leader in the emerging psychedelic pharmaceutical market.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (CURR, VIR, XHG, SANA, SILO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.